Union Budget 2018: The ‘WOW’ Moment for Indian Healthcare?

The 2018-19 Union Budget proposals, presented before the Parliament on February 01, 2018. Especially for those who take keen interest in the Indian healthcare environment, was there a ‘WOW’ moment in the budget? Some say, this long-awaited moment came with … Continue reading

The Next Frontier: Frugal Innovation For High-Tech Drugs

Should drug innovation models remain as expensive as what these are claimed to be now by the global pharma industry, in general? Finding a credible, appropriately quantifiable, and generally acceptable answer to this question is critical. It won’t, then, just … Continue reading

Arbitrary Pricing of Essential Drugs Invites State Intervention

Arbitrary drug pricing has now become a subject of a raging debate, all over the globe. It involves both patented and generic drugs, as we have recently witnessed in the largest pharma market in the world – the United States. … Continue reading

Is Drug Price Control The Key Growth Barrier For Indian Pharma Industry?

The corollary of the above headline could well be: “Are drug price hikes the key growth driver for the Indian Pharmaceutical Market (IPM)?” Whenever the first question, as appears in the headline of this article: “Is drug price control a … Continue reading

India To Expand NLEM 2011: A Step In The Right Direction

Responding to growing discontentment on the flawed National List of Essential Medicines 2011 (NLEM 2011) and equally vociferous demand for its urgent rectification, on May 5, 2015, in a written reply to the Lower House of Indian Parliament (Lok Sabha) … Continue reading

Cheaper Drugs: Happy Patients: Angry Industry

Recent price reductions of a number of cardiovascular and diabetes drugs falling outside the National List of Essential Medicines 2011 (NLEM 2011), have attracted fury of the pharma industry . By a notification dated July 10, 2014, the National Pharmaceutical … Continue reading

Public Healthcare Space: Evaluating Three Fresh Edicts

Medicines constitute a significant cost component of modern healthcare systems across the world. However, in India the situation is even worse, where as per recent studies, drugs contribute as high as around 70 percent of the total treatment cost. This … Continue reading

FDC Saga: Defiant Manufacturers, Sloppy Regulators and Humongous Inaction

“TO SIN BY SILENCE WHEN THEY SHOULD PROTEST MAKES COWARDS OF MEN”       – Abraham Lincoln The ghost of untested, irrational and even of bizarre kind of Fixed Dose Combination (FDC) drugs, which continue to be launched, promoted, prescribed … Continue reading